baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC DIS.CERT. 12/24 22UA/ DE000HC8Z125 /

2024-09-20 9:46:24 PM	Chg.+0.940	Bid9:50:49 PM	Ask9:50:49 PM	Underlying	Strike price	Expiration date	Option type
91.410EUR	+1.04%	- Bid Size: 1,000	- Ask Size: 1,000	BIONTECH SE SPON. AD...	- -	2024-12-31	Call

GlobeNewswire 08-22 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...

GlobeNewswire 08-16 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...

TeleTrader 08-05 BioNTech posts revenue at €128.7 billion in Q2

GlobeNewswire 08-05 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 07-30 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...

GlobeNewswire 07-22 BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024

GlobeNewswire 06-27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...

GlobeNewswire 06-24 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...

GlobeNewswire 06-01 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

TeleTrader 05-06 BioNTech's Q1 revenue slumps 85% to €187.6M

GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

TeleTrader 03-20 BioNTech Q4 revenue plunges 65% to €1.48B

GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 03-11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 03-07 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 03-06 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

GlobeNewswire 01-31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...

GlobeNewswire 01-22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...

UC DIS.CERT. 12/24 22UA/ DE000HC8Z125 /

If you wish to receive reply to your feedback, please provide your email address.